Tepotinib (Tuodekang) dosage adjustment standards and usage methods for different patients

Tepotinib is an oral METtyrosine kinase inhibitor, mainly used for patients with METexon 14 skipping mutation-positive advanced non-small cell lung cancer (NSCLC). By inhibiting the MET signaling pathway, tepotinib blocks tumor cell proliferation and migration. Reasonable dose adjustment and individualized medication regimens are of great significance for improving efficacy, reducing adverse reactions, and ensuring long-term safety.

The recommended standard dose of tepotinib is 450 mg Take once daily with food. In clinical practice, if patients experience intolerable adverse reactions (such as severe edema, abnormal liver function or hematological abnormalities), the dose can be adjusted or the drug temporarily discontinued based on the doctor's evaluation. Common dose adjustment options include reducing to 400mg or 250mg once a day until symptoms subside, and then consider returning to the original dose.

1.Patients with hepatic impairment: Patients with moderate or severe hepatic impairment should use with caution and may need to lower initial dose and strengthen monitoring.

2. Patients with renal insufficiency: Mild to moderate renal dysfunction usually does not require dose adjustment, but patients with severe renal insufficiency require individualized evaluation.

3.Elderly patients or people taking multiple drugs: Pay attention to drug interactions and gradually adjust the dose according to tolerance.

During the course of medication, patients should Regularly review liver and kidney function, hematological indicators and clinical symptoms, especially during the dose adjustment period. When adverse reactions occur, the doctor should be notified promptly and a discontinuation or dose reduction strategy should be adopted. Through scientific management and individualized dose adjustment, tepotinib can be used inWhile ensuring efficacy, it minimizes toxicity and improves patients’ long-term medication safety and compliance.

Reference materials:https://www.drugs.com/